GXV813 Clinical Trials (2026): 1 Studies for Schizophrenia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GXV813 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Schizophrenia) and 142 total planned enrollment. 1 GXV813 clinical trial is actively recruiting at 7 U.S. sites across 6 states. Most recent activity: NCT07467993 (Apr 2027).
Where to Participate: All GXV813 Trial Sites in the U.S. (7 sites across 6 states)
Every actively recruiting GXV813trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AR | Pillar Clinical Research LLC | Bentonville72712 | NCT07467993 | Map |
| CA | CNRI Los Angeles LLC | Pico Rivera90660 | NCT07467993 | Map |
| FL | Segal Institute for Clinical Research | Miami33016 | NCT07467993 | Map |
| GA | CenExel iResearch | Decatur30030 | NCT07467993 | Map |
| IL | Pillar Clinical Research LLC | Chicago60641 | NCT07467993 | Map |
| IL | Uptown Research Institute LLC | Chicago60640 | NCT07467993 | Map |
| MO | Arch Clinical Trials LLC | St Louis63141 | NCT07467993 | Map |
GXV813 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting GXV813 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07467993 | STAR-1Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia | P2 | Schizophrenia | 142 | Mar 2026 |
GXV813 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| STAR-1 | NCT07467993 | P2 | recruiting | Schizophrenia | 142 | — |
All GXV813 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07467993 | STAR-1 | Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia | P2 | recruiting | 142 | Novartis Pharmaceuticals | Mar 2026 |
GXV813 clinical trials: frequently asked questions
- How many GXV813 clinical trials are there?
- 1 GXV813 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GXV813 clinical trials recruiting in 2026?
- Yes — 1 GXV813 trial is actively recruiting in 2026, with 7 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GXV813 being studied for?
- GXV813 is being studied for Schizophrenia. The trials are grouped by indication on this page.
- What phase is GXV813 in?
- GXV813 clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GXV813 clinical trials?
- The lead sponsor across the most GXV813 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GXV813as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: